169 related articles for article (PubMed ID: 34116372)
1. A higher percentage of leukemic blasts with vacuoles predicts unfavorable outcomes in patients with acute myeloid leukemia.
Song J; Shang B; Pei Y; Shi M; Niu X; Dou L; Drokow EK; Xu F; Bai Y; Sun K
Leuk Res; 2021 Oct; 109():106638. PubMed ID: 34116372
[TBL] [Abstract][Full Text] [Related]
2. Blast vacuolization in AML patients indicates adverse-risk AML and is associated with impaired survival after intensive induction chemotherapy.
Ballo O; Stratmann J; Serve H; Steffen B; Finkelmeier F; Brandts C
PLoS One; 2019; 14(9):e0223013. PubMed ID: 31568521
[TBL] [Abstract][Full Text] [Related]
3. Simple acute phase protein score to predict long-term survival in patients with acute myeloid leukemia.
Heini AD; Hugo R; Berger MD; Novak U; Bacher U; Pabst T
Hematol Oncol; 2020 Feb; 38(1):74-81. PubMed ID: 31755141
[TBL] [Abstract][Full Text] [Related]
4. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
DiNardo CD; Garcia-Manero G; Pierce S; Nazha A; Bueso-Ramos C; Jabbour E; Ravandi F; Cortes J; Kantarjian H
Am J Hematol; 2016 Feb; 91(2):227-32. PubMed ID: 26799610
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
6. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
Kern W; Haferlach T; Schoch C; Loffler H; Gassmann W; Heinecke A; Sauerland MC; Berdel W; Buchner T; Hiddemann W
Blood; 2003 Jan; 101(1):64-70. PubMed ID: 12393605
[TBL] [Abstract][Full Text] [Related]
7. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
[TBL] [Abstract][Full Text] [Related]
8. Re-induction therapy in adult patients with acute myeloid leukemia with ≤20 % blasts: A retrospective cohort study.
Kannan KK; Vellanki P; Isom S; Tawfik B; Winter A; Klepin HD; Ellis LR; Bhave RR; Howard D; Manuel M; Dralle S; Lyerly S; Powell BL; Pardee TS
Leuk Res; 2021 Dec; 111():106731. PubMed ID: 34695644
[No Abstract] [Full Text] [Related]
9. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial.
Hyakuna N; Hashii Y; Ishida H; Umeda K; Takahashi Y; Nagasawa M; Yabe H; Nakazawa Y; Koh K; Goto H; Fujisaki H; Matsumoto K; Kakuda H; Yano M; Tawa A; Tomizawa D; Taga T; Adachi S; Kato K
Pediatr Blood Cancer; 2019 Oct; 66(10):e27875. PubMed ID: 31309713
[TBL] [Abstract][Full Text] [Related]
11. The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
Moritake H; Tanaka S; Miyamura T; Nakayama H; Shiba N; Shimada A; Terui K; Yuza Y; Koh K; Goto H; Kakuda H; Saito A; Hasegawa D; Iwamoto S; Taga T; Adachi S; Tomizawa D
Pediatr Blood Cancer; 2021 Jan; 68(1):e28736. PubMed ID: 32991072
[TBL] [Abstract][Full Text] [Related]
12. Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.
Ferrara F; Izzo T; Criscuolo C; Riccardi C; Celentano M; Mele G
Am J Hematol; 2010 Sep; 85(9):687-90. PubMed ID: 20652967
[TBL] [Abstract][Full Text] [Related]
13. The percentage of peripheral blood blasts on day 7 of induction chemotherapy predicts response to therapy and survival in patients with acute myeloid leukemia.
Gao S; Tan Y; Liu X; Su L; Yu P; Han W; Cui J; Li W
Chin Med J (Engl); 2014; 127(2):290-3. PubMed ID: 24438618
[TBL] [Abstract][Full Text] [Related]
14. Tetraploidy/near-tetraploidy acute myeloid leukemia.
Huang L; Wang SA; DiNardo C; Li S; Hu S; Xu J; Zhou W; Goswami M; Medeiros LJ; Tang G
Leuk Res; 2017 Feb; 53():20-27. PubMed ID: 27951415
[TBL] [Abstract][Full Text] [Related]
15. MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation.
Seipel K; Messerli C; Wiedemann G; Bacher U; Pabst T
Leuk Res; 2020 Feb; 89():106296. PubMed ID: 31927137
[TBL] [Abstract][Full Text] [Related]
16. Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: A single center experience of 355 consecutive patients.
Hilberink J; Hazenberg C; van den Berg E; Mulder A; Schuringa JJ; van der Helm L; de Groot M; Choi G; de Bock GH; Vellenga E; Ammatuna E; Huls G
Leuk Res; 2019 May; 80():33-39. PubMed ID: 30954622
[TBL] [Abstract][Full Text] [Related]
17. In situ RHAMM protein expression in acute myeloid leukemia blasts suggests poor overall survival.
Tzankov A; Strasser U; Dirnhofer S; Menter T; Arber C; Jotterand M; Rovo A; Tichelli A; Stauder R; Günthert U
Ann Hematol; 2011 Aug; 90(8):901-9. PubMed ID: 21274712
[TBL] [Abstract][Full Text] [Related]
18. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy.
Short NJ; Benton CB; Chen HC; Qiu P; Gu L; Pierce S; Brandt M; Maiti A; Min TL; Naqvi K; Quintas-Cardama A; Konopleva M; Kadia T; Cortes J; Garcia-Manero G; Ravandi F; Jabbour E; Kantarjian H; Andreeff M
Am J Hematol; 2016 Dec; 91(12):1221-1226. PubMed ID: 27474808
[TBL] [Abstract][Full Text] [Related]
19. The Time to Clearance of Peripheral Blood Blasts Predicts Complete Remission and Survival in Chinese Adults with Acute Myeloid Leukemia.
Li X; Zhu H; Zhang Y; Zhao W; Mi J; Hu J; Li J
Acta Haematol; 2016; 135(4):217-23. PubMed ID: 26967450
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implication of N-RAS gene mutations in Egyptian adult acute myeloid leukemia.
Elghannam DM; Abousamra NK; Shahin DA; Goda EF; Azzam H; Azmy E; El-Din MS; El-Refaei MF
Egypt J Immunol; 2009; 16(1):9-15. PubMed ID: 20726318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
